We use first and third-party cookies to offer our services and collect statistical data. If you continue browsing this website you accept their use. More information Accept
PRODUCTS / CNS PHARMACEUTICALS
CNS_PHARMA_METAS_SERVICE_ALT

CNS PHARMACEUTICALS

Lesvi offers one of the most comprehensive product portfolios in CNS pharmaceuticals.
Product Indication Dosage form Strength
Levomethadone ** Opioids substitution Oral solution 5mg/ ml (bottle 500ml and 1000ml)
Levomethadone ** Severe pain Oral drops, solution 5mg/ ml (bottle 20ml)
Melperone Psychomotor agitation and sleep Film-coated tablets 10 mg, 25 mg,  50mg and  100 mg
Melperone Forte Psychomotor agitation and sleep Oral solution 25mg/ 5 ml
Memantine hydrochloride Alzheimer's disease Film-coated tablets 5, 10, 15 and 20 mg
Memantine hydrochloride Alzheimer's disease Oral solution 10 mg/ml
Methocarbamol Muscle spasms, pain Film-coated tablets 750 mg
Methocarbamol Muscle spasms, pain Film-coated tablets 500, 1000 and 1500 mg
Midazolam Epilepsy Oral solution 2,5 mg/ 0,5 ml
5 mg/ 1 ml
7,5 mg/ 1,5 ml               
10 mg/ 2 ml
Olanzapine Psychosis, schizophrenia Film-coated tablets 2.5, 5, 7.5, 10, 15 and 20 mg
Olanzapine Psychosis, schizophrenia Orodispersable tablets 5, 10, 15 and 20 mg
Opipramol Depression / Anxiety Film-coated tablets 50, 100 and 150 mg
Pipamperone Sleep disorders and psychomotor Tablets 40 and 120 mg
Pipamperone Sleep disorders and psychomotor Oral solution 20mg/ 5 ml
Piracetam Alzheimer Film-coated tablets 800 & 1200 mg
Piracetam Alzheimer Oral solution 333 mg/ml
Piracetam Alzheimer Solution for injection 200mg/ ml
Pramipexol Parkinson's IR tablets 0.088, 0.18, 0.35, 0.7 and 1.1 mg
Pregabaline * Neuropathic pain Tablets 25, 50, 75, 100, 150, 200, 225 and 300 mg
Promethazine Agitation and restlessness Injection 25mg/ ml
FDF PRODUCT PORTFOLIO

[*] Differentiated product
[**] Opioid

Listed products protected by valid patents are developed solely for purposes related to the development, preparation and submission of information to obtain a Marketing Authorisation. In particular these products are under development for uses related to the activities stated in Art. 10.6 of Directive 2001/83/EC amended by the Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004, i.e. activities carried out to obtain a Marketing Authorisation. None of the products are offered for sale or supplied to countries in which they could be in conflict with valid patents.


© Neuraxpharm / LESVI. All rights reserved.